New Wegovy pill versus fat jabs – best and worst for fat loss and preventing heart attack revealed

The first head-to-head trial comparing the WEGOVY pill to other obesity drugs has found that it's equally effective for weight loss but may lack the same heart benefits as its rivals. Produced by Novo Nordisk, WEGOVY is a new GLP-1 pill now available in the UK, marking a significant step in weight management treatments. This revelation is crucial as it highlights the importance of considering both weight loss and cardiovascular health when choosing weight management solutions, potentially influencing future treatment decisions and patient outcomes.